Pharmaceuticals News and Research

RSS

Researchers discover novel compound to combat drug resistant malaria

Novartis announced today that scientists at the Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria.

3 Sep 2010

Shanghai SynTheAll Pharmaceuticals receives ISO 14001 certification

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its manufacturing subsidiary, Shanghai SynTheAll Pharmaceuticals Co. Ltd. (STA) passed the ISO 14001: 2004 inspection conducted by SGS Group on July 1 and received formal ISO 14001 certification on July 30.

3 Sep 2010

Biologists find daily exercise as a heritable trait

Biologists at the University of California, Riverside have found that voluntary activity, such as daily exercise, is a highly heritable trait that can be passed down genetically to successive generations.

2 Sep 2010

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, announced today the final data set from its Phase 3 study of Ketotransdel® (TDLP-110) at the 13th World Congress on Pain in Montreal, Canada.

2 Sep 2010

iBio and CMB enter development and marketing collaboration with GE Healthcare

iBio, Inc., its development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB), and GE Healthcare, a unit of General Electric Company, today announced their entry into an agreement to jointly develop and globally market manufacturing solutions for biopharmaceuticals and vaccines based upon their respective proprietary technologies.

2 Sep 2010

AHF proposes innovative solution to resolve AIDS drug crisis in Florida

As the State of Florida grapples with a budget shortfall that is crippling its AIDS Drug Assistance Program and forcing the state to place more than 1,300 low-income Floridians on waiting lists to access lifesaving AIDS medications, AIDS Healthcare Foundation has proposed an innovative solution to state health officials and seven leading AIDS drug companies that would create a public/private partnership to resolve the drug crisis and get vulnerable Florida AIDS patients on to lifesaving antiretroviral treatment.

2 Sep 2010

Lilly's Evista method patents upheld through March of 2014

Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company's method-of-use patents for Evista® (raloxifene HCl tablets) are valid. These patents provide protection for Evista in the U.S. through March of 2014.

2 Sep 2010

Researchers develop new technique to trace counterfeit drugs

Counterfeiting of drugs is a huge industry with an annual turnover of more than SEK 500 billion. In Africa the situation is extremely serious. Half of the malaria medication sold there could be ineffective or even harmful. Researchers from Lund and the UK have now developed a technique that could resolve the situation.

2 Sep 2010

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and Mexico.

2 Sep 2010

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with Lytixar (LTX-109) treatment of skin infections caused by Gram positive bacteria.

2 Sep 2010

First Edition: September 2, 2010

Today's headlines include reports about a new study examining the impact of the health overhaul on the small business workforce.

2 Sep 2010

XARELTO achieves net clinical benefit in treatment of patients with DVT

Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.

2 Sep 2010

First Phase I/II clinical trial to test MK-0752 in patients with advanced pancreatic cancer

Cancer Research UK's Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat.

2 Sep 2010

Cannabis Science issues statement on marijuana study for post-surgery neuropathic pain

Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment.

2 Sep 2010

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.

2 Sep 2010

Promega to provide FuGENE HD Transfection Reagent throughout life science market

Promega Corporation announces it will provide FuGENE HD Transfection Reagent throughout the life science market. The comprehensive, direct use offering from Promega means any life scientist can utilize FuGENE technology with no licensing requirements. FuGENE HD enables the transfection of DNA into many cell types with high efficiency and little-to-no toxicity.

2 Sep 2010

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint.

2 Sep 2010

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Pfizer Inc. and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx.

2 Sep 2010

Asuragen launches KRAS, BRAF mutational testing in CLIA laboratory

Asuragen, Inc., a leader in molecular diagnostics and nucleic acid-based pharmacogenomics services, announced today that it has launched KRAS and BRAF mutational testing services in its CAP-accredited CLIA laboratory.

2 Sep 2010

Celator Pharmaceuticals raises $20 million in Series D private equity financing

Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.

2 Sep 2010

Pharmaceuticals News and Research

Researchers discover novel compound to combat drug resistant malaria

Shanghai SynTheAll Pharmaceuticals receives ISO 14001 certification

Biologists find daily exercise as a heritable trait

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

iBio and CMB enter development and marketing collaboration with GE Healthcare

AHF proposes innovative solution to resolve AIDS drug crisis in Florida

Lilly's Evista method patents upheld through March of 2014

Researchers develop new technique to trace counterfeit drugs

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

First Edition: September 2, 2010

XARELTO achieves net clinical benefit in treatment of patients with DVT

First Phase I/II clinical trial to test MK-0752 in patients with advanced pancreatic cancer

Cannabis Science issues statement on marijuana study for post-surgery neuropathic pain

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Promega to provide FuGENE HD Transfection Reagent throughout life science market

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Asuragen launches KRAS, BRAF mutational testing in CLIA laboratory

Celator Pharmaceuticals raises $20 million in Series D private equity financing

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence